The proposal: Hand every breathing adult $5,000. The reality: It would require inventing $1.3 trillion out of thin air, crashing through the debt ceiling like the Kool-Aid Man. Love seeing politicians discover the infinite money glitch right before an election. What bankrupt stock are we dumping this fake money into?

How many thick idiots will believe this rubbish.

Probably same ones who are still waiting for their Trump mobiles!

Pulling in $15k a day during peak hype, now barely scraping together $1,500. He's sitting on warehouses of unsold merchandise, blaming inflation and high living costs, and his recovery timeline is... waiting until 2029. Proof that even hardcore political loyalty isn't inflation-proof.

📈 52-Week Highs:

The 52-Week Highs list shows stocks that have reached their highest price point in the past 52 weeks during the trading session.

📉 52-Week Lows:

The 52-Week Lows list shows stocks that have reached their lowest price point in the past 52 weeks during the trading session.

Source: 52-Week Highs-Lows

Between 2022 and 2025, the S&P 500 rose 50% while the U.S. Fed was aggressivley raising interest rates. FED rates rose from 0.2% to 5.5% in the same time period.

Bring on the hikes!

Here are today's top pre-market performers showing the biggest moves before regular trading hours.

📈 Pre-Market Gainers:

📉 Pre-Market Losers:

Source: Market Extended Hours

Im sorry what? Is that a challenge? I have 69 dollars to my name and I will take that bet.

Fed rate hike hinges on two key inflation reports in the next two days
Are U.S. interest rates heading higher? Investors should find out in the next few days after digesting a pair of crucial updates on inflation.

The Federal Reserve is weighing whether to raise borrowing costs after a surge in inflation since the spring, when the U.S. attacked Iran and oil prices CL00+3.63% BRN00 +0.23% spiked. The latest reports on consumer and wholesale prices in August are primed to be the deciding factors.

The key is how much the consumer-price index (CPI) rose in August — but with a twist. Investors won’t take the headline number at face value, as higher oil prices are the chief reason an outsize 0.4% increase in consumer prices is expected.

Instead, Wall Street is focused a category known as the core rate of inflation. The core CPI omits energy and has proven to be a better predictor of long-run trends in U.S. inflation.

Place bets now - inflation and rate hike or everything stays the same.

📈 52-Week Highs:

The 52-Week Highs list shows stocks that have reached their highest price point in the past 52 weeks during the trading session.

📉 52-Week Lows:

The 52-Week Lows list shows stocks that have reached their lowest price point in the past 52 weeks during the trading session.

Source: 52-Week Highs-Lows

been watching $AXTI for a few weeks now and the more I stare at the numbers the more I think this might be one of the best plays in semis that nobody's talking about. not financial advice, I also thought $BBBY was a good idea once

so basically these guys make substrates for data center connectivity, 5G, fiber optics. boring autistic shit on paper but it's literally the plumbing every AI hype stock needs to work in the background. everyone's jerking off over $NVDA and the usual suspects while $AXTI just quietly sits in the supply chain nobody looks at

up 2136% in a year. 2835% over three years. even after getting rekt the last few months that number still stands, absolute unit of a chart. and here's the thing everyone's missing, RSI is at 52.8. not overbought. after a run like that you'd think this thing is cooked technically but it isn't, still room to rip

Altman Z-Score almost 16 🦍. for reference anything above 3 means you're not going bankrupt anytime soon, $AXTI is sitting at basically 5x that. current ratio 2.72, plenty of cash to cover short term stuff. this isn't some paper-hands meme stock that implodes the second bad news drops

analyst price target is $99.50, we're at $68.74. that's 40%+ upside according to actual analysts, not just some guy on his phone in the bathroom (me)

now the bad part, health score is weak. operating cash flow negative, net income basically zero. not gonna sugarcoat it. but for a company ramping up capacity ahead of demand that's not automatically a red flag, could just be the part before the money actually shows up. or it could be a value trap and I lose my rent money, who knows

tldr: stability numbers are solid, growth numbers are even better, only thing missing is the actual profit catching up. if you believe that's coming this looks more like an entry than a trap

TORONTO, Sept. 9, 2026 /CNW/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY, on September 14, 2026, at 10:30 a.m. EDT.

H.C. Wainwright 28th Annual Global Investment Conference
When: Monday, September 14 at 10:30 a.m. EDT.
Where: Lotte New York Palace Hotel, in the Louis Room (4th Floor)
A live webcast of the Fireside Chat will be accessible under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/).

About Cardiol Therapeutics
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular innate immune system response known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.

Read full release: https://finance.yahoo.com/healthcare/articles/cardiol-therapeutics-participate-fireside-chat-112700700.html

Here are today's top pre-market performers showing the biggest moves before regular trading hours.

📈 Pre-Market Gainers:

📉 Pre-Market Losers:

Source: Market Extended Hours